Emerging nanotechnology based combination therapies of taxanes for multiple drug-resistant cancers

References

• A Antolin A, Workman P, Mestres J, Al-Lazikani B. 2016. Polypharmacology in precision oncology: current applications and future prospects. Curr Pharm Des. 22(46):6935–6945.
   PubMed Web of Science ®Google Scholar
• Abidi A. 2013. Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J Pharmacol Pharmacother. 4(4):230–237.
   PubMedGoogle Scholar
• Abou-El-Naga AM, Mutawa G, El-Sherbiny IM, Mousa SA. 2018. Activation of polymeric nanoparticle intracellular targeting overcomes chemodrug resistance in human primary patient breast cancer cells. Int J Nanomedicine. 13:8153–8164.
   PubMed Web of Science ®Google Scholar
• Assanhou AG, Li W, Zhang L, Xue L, Kong L, Sun H, Mo R, Zhang C. 2015. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment. Biomaterials. 73:284–295.
   PubMed Web of Science ®Google Scholar
• Banstola A, Pham TT, Jeong J-H, Yook S. 2019. Polydopamine-tailored paclitaxel-loaded polymeric microspheres with adhered NIR-controllable gold nanoparticles for chemo-phototherapy of pancreatic cancer. Drug Deliv. 26(1):629–640.
   PubMed Web of Science ®Google Scholar
• Bao Y, Deng Q, Li Y, Zhou S. 2018. Engineering docetaxel-loaded micelles for non-small cell lung cancer: a comparative study of microfluidic and bulk nanoparticle preparation. RSC Adv. 8(56):31950–31966.
   Web of Science ®Google Scholar
• Bar-Zeev M, Livney YD, Assaraf YG. 2017. Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance. Drug Resist Updat. 31:15–30.
   PubMed Web of Science ®Google Scholar
• Bhunia S, Radha V, Chaudhuri A. 2017. CDC20siRNA and paclitaxel co-loaded nanometric liposomes of a nipecotic acid-derived cationic amphiphile inhibit xenografted neuroblastoma. Nanoscale. 9(3):1201–1212.
   PubMed Web of Science ®Google Scholar
• Borgnia MJ, Eytan GD, Assaraf YG. 1996. Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 271(6):3163–3171.
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. 1999. The multidrug resistance protein family. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1461(2):347–357.
   PubMed Web of Science ®Google Scholar
• Bouchard H, Semiond D, Risse ML, Vrignaud P. 2012. Novel taxanes: cabazitaxel case study. Analogue‐Based Drug Discovery. III:319–341.
   Google Scholar
• Bteich J, Ernsting MJ, Mohammed M, Kiyota T, McKee TD, Trikha M, Lowman HB, Sokoll KK. 2018. Nanoparticle formulation derived from carboxymethyl cellulose, polyethylene glycol, and cabazitaxel for chemotherapy delivery to the brain. Bioconjug Chem. 29(6):2009–2020.
   PubMed Web of Science ®Google Scholar
• Bukowski K, Kciuk M, Kontek R. 2020. Mechanisms of multidrug resistance in cancer chemotherapy. IJMS. 21(9):3233.
   Google Scholar
• Calzoni E, Cesaretti A, Polchi A, Di Michele A, Tancini B, Emiliani C. 2019. Biocompatible polymer nanoparticles for drug delivery applications in cancer and neurodegenerative disorder therapies. JFB. 10(1):4.
   Google Scholar
• Cascorbi I. 2011. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Drug Transporters. Berlin: Springer; p. 261–283.
   Google Scholar
• Chen W, Guo M, Wang S. 2016. Anti prostate cancer using PEGylated bombesin containing, cabazitaxel loading nano-sized drug delivery system. Drug Dev Ind Pharm. 42(12):1968–1976.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li N, Yang Y, Liu Y. 2015. A dual targeting cyclodextrin/gold nanoparticle conjugate as a scaffold for solubilization and delivery of paclitaxel. RSC Adv. 5(12):8938–8941.
   Web of Science ®Google Scholar
• Cheng Y, Ou Z, Li Q, Yang J, Hu M, Zhou Y, Zhuang X, Zhang ZJ, Guan S. 2019. Cabazitaxel liposomes with aptamer modification enhance tumor-targeting efficacy in nude mice. Mol Med Rep. 19(1):490–498.
   PubMed Web of Science ®Google Scholar
• Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD. 2002. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther. 300(1):97–104.
   PubMed Web of Science ®Google Scholar
• Cho H, Lai TC, Tomoda K, Kwon GS. 2015. Polymeric micelles for multi-drug delivery in cancer. Aaps Pharmscitech. 16(1):10–20.
   PubMed Web of Science ®Google Scholar
• Choi J-S, Park J-S. 2017. Development of docetaxel nanocrystals surface modified with transferrin for tumor targeting. Drug Des Devel Ther. 11:17–26.
   PubMed Web of Science ®Google Scholar
• Cole SP. 2014. Multidrug resistance protein 1 (MRP1, ABCC1), a “multitasking” ATP-binding cassette (ABC) transporter. J Biol Chem. 289(45):30880–30888.
   PubMed Web of Science ®Google Scholar
• Cole S, Bhardwaj G, Gerlach J, Mackie J, Grant C, Almquist K, Stewart A, Kurz E, Duncan A, Deeley RG. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258(5088):1650–1654.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R. 2012. US food and drug administration approval overview in metastatic breast cancer. J Clin Oncol. 30(14):1705–1711.
   PubMed Web of Science ®Google Scholar
• da Rocha MCO, da Silva PB, Radicchi MA, Andrade BYG, de Oliveira JV, Venus T, Merker C, Estrela-Lopis I, Longo JPF, Báo SN. 2020. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells. J Nanobiotechnol. 18(1):1–20.
   PubMed Web of Science ®Google Scholar
• Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R. 2004. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res. 10(24):8147–8151.
   PubMed Web of Science ®Google Scholar
• Desale JP, Swami R, Kushwah V, Katiyar SS, Jain S. 2018. Chemosensitizer and docetaxel-loaded albumin nanoparticle: overcoming drug resistance and improving therapeutic efficacy. Nanomedicine. 13(21):2759–2776.
   PubMed Web of Science ®Google Scholar
• Dhillon PK, Mathur P, Nandakumar A, Fitzmaurice C, Kumar GA, Mehrotra R, Shukla DK, Rath GK, Gupta PC, Swaminathan R, et al. 2018. The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016. Lancet Oncol. 19(10):1289–1306.
   PubMed Web of Science ®Google Scholar
• Dieras V, Lortholary A, Laurence V, Delva R, Girre V, Livartowski A, Assadourian S, Semiond D, Pierga J. 2013. Cabazitaxel in patients with advanced solid tumours: results of a phase I and pharmacokinetic study. Eur J Cancer. 49(1):25–34.
   PubMed Web of Science ®Google Scholar
• Doddapaneni R, Patel K, Chowdhury N, Singh M. 2017. Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer. Sci Rep. 7(1):1–11.
   PubMedGoogle Scholar
• Eloy JO, Petrilli R, Topan JF, Antonio HMR, Barcellos JPA, Chesca DL, Serafini LN, Tiezzi DG, Lee RJ, Marchetti JM. 2016. Co-loaded paclitaxel/rapamycin liposomes: development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B Biointerfaces. 141:74–82.
   PubMed Web of Science ®Google Scholar
• Farooq MU, Novosad V, Rozhkova EA, Wali H, Ali A, Fateh AA, Neogi PB, Neogi A, Wang Z. 2018. Gold nanoparticles-enabled efficient dual delivery of anticancer therapeutics to HeLa cells. Sci Rep. 8(1):1–12.
   PubMedGoogle Scholar
• Feng L, Mumper RJ. 2013. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 334(2):157–175.
   PubMed Web of Science ®Google Scholar
• Fletcher JI, Haber M, Henderson MJ, Norris MD. 2010. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 10(2):147–156.
   PubMed Web of Science ®Google Scholar
• Fletcher JI, Williams RT, Henderson MJ, Norris MD, Haber M. 2016. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updat. 26:1–9.
   PubMed Web of Science ®Google Scholar
• Gad A, Kydd J, Piel B, Rai P. 2016. Targeting cancer using polymeric nanoparticle mediated combination chemotherapy. Int J Nanomed Nanosurg. 2(3):1–12.
   Google Scholar
• Gagliardi A, Giuliano E, Eeda V, Fresta M, Bulotta S, Awasthi V, Cosco D. 2021. Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol. 12:601626.
   PubMed Web of Science ®Google Scholar
• Ganellin CR, Rotella DP, Fischer J. 2013. Analogue-based Drug Discovery III. Weinheim: Wiley-VCH.
   Google Scholar
• Gao Y, Chen J, Zhang X, Xie H, Wang Y, Guo S. 2017. Quantification of paclitaxel and polyaspartate paclitaxel conjugate in beagle plasma: application to a pharmacokinetic study. J Chromatogr Sci. 55(3):222–231.
   PubMed Web of Science ®Google Scholar
• Gdowski AS, Ranjan A, Sarker MR, Vishwanatha JK. 2017. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine. 12(17):2083–2095.
   PubMed Web of Science ®Google Scholar
• Gligorov J, Lotz JP. 2004. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 9(S2):3–8.
   PubMedGoogle Scholar
• Golombek SK, May J-N, Theek B, Appold L, Drude N, Kiessling F, Lammers T. 2018. Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev. 130:17–38.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. 2006. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 7(8):1041–1053.
   PubMed Web of Science ®Google Scholar
• Green M, Manikhas G, Orlov S, Afanasyev B, Makhson A, Bhar P, Hawkins M. 2006. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 17(8):1263–1268.
   PubMed Web of Science ®Google Scholar
• Guo Y, He W, Yang S, Zhao D, Li Z, Luan Y. 2017. Co-delivery of docetaxel and verapamil by reduction-sensitive PEG-PLGA-SS-DTX conjugate micelles to reverse the multi-drug resistance of breast cancer. Colloids Surf B Biointerfaces. 151:119–127.
   PubMed Web of Science ®Google Scholar
• Guo X, Zhao Z, Chen D, Qiao M, Wan F, Cun D, Sun Y, Yang M. 2019. Co-delivery of resveratrol and docetaxel via polymeric micelles to improve the treatment of drug-resistant tumors. Asian J Pharm Sci. 14(1):78–85.
   PubMed Web of Science ®Google Scholar
• Hamed AR, Abdel-Azim NS, Shams KA, Hammouda FM. 2019. Targeting multidrug resistance in cancer by natural chemosensitizers. Bull Natl Res Cent. 43(1):8.
   Google Scholar
• Han X, Gong F, Sun J, Li Y, Liu X, Chen D, Liu J, Shen Y. 2018. Glutathione-responsive core cross-linked micelles for controlled cabazitaxel delivery. J Nanopart Res. 20(2):1–15.
   Web of Science ®Google Scholar
• Han EK-H, Tahir S, Cherian S, Collins N, Ng S. 2000. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer. 83(1):83–88.
   PubMed Web of Science ®Google Scholar
• He Z, Schulz A, Wan X, Seitz J, Bludau H, Alakhova DY, Darr DB, Perou CM, Jordan R, Ojima I, et al. 2015. Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation. J Control Release. 208:67–75.
   PubMed Web of Science ®Google Scholar
• Hennenfent K, Govindan R. 2006. Novel formulations of taxanes: a review. Old wine in a new bottle? Annals Oncol. 17(5):735–749.
   PubMed Web of Science ®Google Scholar
• Ho MY, Mackey JR. 2014. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res. 6:253–259.
   PubMed Web of Science ®Google Scholar
• Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, Bates SE. 2002. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther. 1(6):696–702.
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Zhang L. 2009. Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab. 10(8):836–841.
   PubMed Web of Science ®Google Scholar
• Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. 2008. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev. 34(7):592–602.
   PubMed Web of Science ®Google Scholar
• Ji W, Wang B, Fan Q, Xu C, He Y, Chen Y. 2017. Chemosensitizing indomethacin-conjugated dextran-based micelles for effective delivery of paclitaxel in resistant breast cancer therapy. PLOS One. 12(7):e0180037.
   PubMed Web of Science ®Google Scholar
• Jin G, Jin M, Jin Z, Gao Z, Yin X. 2016. Docetaxel-loaded PEG-albumin nanoparticles with improved antitumor efficiency against non-small cell lung cancer. Oncol Rep. 36(2):871–876.
   PubMed Web of Science ®Google Scholar
• Jin J, Wu X, Yin J, Li M, Shen J, Li J, Zhao Y, Zhao Q, Wu J, Wen Q, et al. 2019. Identification of genetic mutations in cancer: challenge and opportunity in the new era of targeted therapy. Front Oncol. 9:263.
   PubMed Web of Science ®Google Scholar
• Jones B. 1990. Hypersensitivity reactions from taxol. J Clin. 8(7):1263–1268.
   Google Scholar
• Jordan M. 2002. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents. 2(1):1–17.
   PubMedGoogle Scholar
• Jordan MA, Wilson L. 2004. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4(4):253–265.
   PubMed Web of Science ®Google Scholar
• Jose S, Cinu TA, Sebastian R, Shoja M, Aleykutty N, Durazzo A, Lucarini M, Santini A, Souto EB. 2019. Transferrin-conjugated docetaxel–PLGA nanoparticles for tumor targeting: influence on MCF-7 cell cycle. Polymers. 11(11):1905.
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta (BBA)-Biomembranes. 455(1):152–162.
   PubMed Web of Science ®Google Scholar
• Kang X-j, Wang H-y, Peng H-g, Chen B-f, Zhang W-y, Wu A-h, Xu Q, Huang Y-z. 2017. Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy. Acta Pharmacol Sin. 38(6):885–896.
   PubMed Web of Science ®Google Scholar
• Kapse-Mistry S, Govender T, Srivastava R, Yergeri M. 2014. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol. 5:159.
   PubMed Web of Science ®Google Scholar
• Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, Seo MH. 2001. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 72(1–3):191–202.
   PubMed Web of Science ®Google Scholar
• Kommineni N, Mahira S, Domb AJ, Khan W. 2019. Cabazitaxel-loaded nanocarriers for cancer therapy with reduced side effects. Pharmaceutics. 11(3):141.
   Web of Science ®Google Scholar
• Kumar L, Deshpande A, Page A. 2015. Super generics/improved therapeutic entities: an approach to fulfill unmet medical needs and extending market exclusivity of generic medicines. Int J Pharm Pharm Sci. 7(2):25–29.
   Google Scholar
• Lei M, Sha S, Wang X, Wang J, Du X, Miao H, Zhou H, Bai E, Shi J, Zhu Y. 2019. Co-delivery of paclitaxel and gemcitabine via a self-assembling nanoparticle for targeted treatment of breast cancer. RSC Adv. 9(10):5512–5520.
   PubMed Web of Science ®Google Scholar
• Li ZL, Huang YS, Xiong XY, Qin X, Luo YY. 2017. Synthesis, characterisation and in vitro release of paclitaxel-loaded polymeric micelles. Micro Nano Letters. 12(3):191–194.
   Web of Science ®Google Scholar
• Li J, Xu R, Lu X, He J, Jin S. 2017. A simple reduction-sensitive micelles co-delivery of paclitaxel and dasatinib to overcome tumor multidrug resistance. Int J Nanomedicine. 12:8043–8056.
   PubMed Web of Science ®Google Scholar
• Lin F, Wen D, Wang X, Mahato RI. 2019. Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer. Biomaterials. 192:95–108.
   PubMed Web of Science ®Google Scholar
• Liu J, Cheng H, Han L, Qiang Z, Zhang X, Gao W, Zhao K, Song Y. 2018. Synergistic combination therapy of lung cancer using paclitaxel-and triptolide-coloaded lipid–polymer hybrid nanoparticles. Drug Des Devel Ther. 12:3199–3209.
   PubMed Web of Science ®Google Scholar
• Loiseau A, Boudon J, Oudot A, Moreau M, Boidot R, Chassagnon R, Mohamed Saïd N, Roux S, Mirjolet C, Millot N. 2019. Titanate nanotubes engineered with gold nanoparticles and docetaxel to enhance radiotherapy on xenografted prostate tumors. Cancers. 11(12):1962.
   Web of Science ®Google Scholar
• Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. 2003. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther. 74(4):364–371.
   PubMed Web of Science ®Google Scholar
• Ma B, Zhuang W, Liu G, Wang Y. 2018. A biomimetic and pH-sensitive polymeric micelle as carrier for paclitaxel delivery. Regen Biomater. 5(1):15–24.
   PubMed Web of Science ®Google Scholar
• Mahira S, Kommineni N, Husain GM, Khan W. 2019. Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: a new insight into nanomedicine based combinational chemotherapy for prostate cancer. Biomed Pharmacother. 110:803–817.
   PubMed Web of Science ®Google Scholar
• Makhoba XH, Viegas C, Jr Mosa RA, Viegas FP, Pooe OJ. 2020. Potential impact of the multi-target drug approach in the treatment of some complex diseases. Drug Des Devel Ther. 14:3235–3249.
   PubMed Web of Science ®Google Scholar
• Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. 2003. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat. 6(5):271–279.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. 2017. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 7(3):339–348.
   PubMed Web of Science ®Google Scholar
• Mao Q, Unadkat JD. 2005. Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps J. 7(1):E118–E133.
   PubMed Web of Science ®Google Scholar
• Mao Y, Li X, Chen G, Wang S. 2016. Thermosensitive hydrogel system with paclitaxel liposomes used in localized drug delivery system for in situ treatment of tumor: better antitumor efficacy and lower toxicity. J Pharm Sci. 105(1):194–204.
   PubMed Web of Science ®Google Scholar
• Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. 2007. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 6(5):609–621.
   PubMed Web of Science ®Google Scholar
• Meng J, Guo F, Xu H, Liang W, Wang C, Yang X-D. 2016. Combination therapy using co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells in vivo. Sci Rep. 6(1):22390.
   PubMedGoogle Scholar
• Milutinović MG, Stanković MS, Cvetković DM, Topuzović MD, Mihailović VB, Marković SD. 2015. Antioxidant and anticancer properties of leaves and seed cones from European yew (Taxus baccata L.). Arch Biol Sci. 67(2):525–534.
   Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. 2021. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 20(2):101–124.
   PubMed Web of Science ®Google Scholar
• Odeh F, Naffa R, Azzam H, Mahmoud IS, Alshaer W, Al Bawab A, Ismail S. 2019. Co-encapsulation of thymoquinone with docetaxel enhances the encapsulation efficiency into PEGylated liposomes and the chemosensitivity of MCF7 breast cancer cells to docetaxel. Heliyon. 5(11):e02919.
   PubMed Web of Science ®Google Scholar
• Olusanya TO, Haj Ahmad RR, Ibegbu DM, Smith JR, Elkordy AA. 2018. Liposomal drug delivery systems and anticancer drugs. Molecules. 23(4):907.
   PubMed Web of Science ®Google Scholar
• Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. 2003. Mechanisms of taxol resistance related to microtubules. Oncogene. 22(47):7280–7295.
   PubMed Web of Science ®Google Scholar
• Paciotti GF, Zhao J, Cao S, Brodie PJ, Tamarkin L, Huhta M, Myer LD, Friedman J, Kingston DG. 2016. Synthesis and evaluation of paclitaxel-loaded gold nanoparticles for tumor-targeted drug delivery. Bioconjug Chem. 27(11):2646–2657.
   PubMed Web of Science ®Google Scholar
• Paller CJ, Antonarakis ES. 2011. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 5:117–124.
   PubMed Web of Science ®Google Scholar
• Park DC, Kim JH, Lew YO, Kim DH, Namkoong SE. 2004. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol. 92(1):59–63.
   PubMed Web of Science ®Google Scholar
• Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres M. d P, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, et al. 2018. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 16(1):1–33.
   PubMed Web of Science ®Google Scholar
• Pean E, Demolis P, Moreau A, Hemmings RJ, O'Connor D, Brown D, Shepard T, Abadie E, Pignatti F. 2012. The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 17(4):543–549.
   PubMed Web of Science ®Google Scholar
• Pereira S, Egbu R, Jannati G, Al-Jamal WT. 2016. Docetaxel-loaded liposomes: the effect of lipid composition and purification on drug encapsulation and in vitro toxicity. Int J Pharm. 514(1):150–159.
   PubMed Web of Science ®Google Scholar
• Perez EA. 2009. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 8(8):2086–2095.
   PubMed Web of Science ®Google Scholar
• Ren G, Liu D, Guo W, Wang M, Wu C, Guo M, Ai X, Wang Y, He Z. 2016. Docetaxel prodrug liposomes for tumor therapy: characterization, in vitro and in vivo evaluation. Drug Deliv. 23(4):1272–1281.
   PubMed Web of Science ®Google Scholar
• Rodallec A, Brunel J-M, Giacometti S, Maccario H, Correard F, Mas E, Orneto C, Savina A, Bouquet F, Lacarelle B, et al. 2018. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer. Int J Nanomedicine. 13:3451–3465.
   PubMed Web of Science ®Google Scholar
• Rowinsky M, Eric K. 1997. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med. 48(1):353–374.
   PubMed Web of Science ®Google Scholar
• Shah AK, Wyandt CM, Stodghill SP. 2013. Physico chemical characterization of a novel anti-cancer agent and its comparison to Taxol(®). Drug Dev Ind Pharm. 39(1):89–101.
   PubMed Web of Science ®Google Scholar
• Sharom FJ. 2014. Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function. Front Oncol. 4:41.
   PubMedGoogle Scholar
• Shen Q, Shen Y, Jin F, Du Y-z, Ying X-y. 2020. Paclitaxel/hydroxypropyl-β-cyclodextrin complex-loaded liposomes for overcoming multidrug resistance in cancer chemotherapy. J Liposome Res. 30(1):12–20.
   PubMed Web of Science ®Google Scholar
• Shi Y, Van der Meel R, Chen X, Lammers T. 2020. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 10(17):7921–7924.
   PubMed Web of Science ®Google Scholar
• Shi W, Yuan Y, Chu M, Zhao S, Song Q, Mu X, Xu S, Zhang Z, Yang K. 2016. Radiosensitization of TPGS-emulsified docetaxel-loaded poly(lactic-co-glycolic acid) nanoparticles in CNE-1 and A549 cells . J Biomater Appl. 30(8):1127–1141.
   PubMed Web of Science ®Google Scholar
• Singh S, Dash AK. 2009. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. Critical Reviews™ in Therapeutic Drug Carrier Systems. 26(4):333–372.
   PubMed Web of Science ®Google Scholar
• Sohail MF, Rehman M, Sarwar HS, Naveed S, Salman O, Bukhari NI, Hussain I, Webster TJ, Shahnaz G. 2018. Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends. Int J Nanomedicine. 13:3145–3161.
   PubMed Web of Science ®Google Scholar
• Stavrovskaya A, Rybalkina EY. 2018. Recent advances in the studies of molecular mechanisms regulating multidrug resistance in cancer cells. Biochemistry. 83(7):779–786.
   PubMed Web of Science ®Google Scholar
• Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B. 2019. Gold nanoparticles in cancer treatment. Mol Pharm. 16(1):1–23.
   PubMedGoogle Scholar
• Tang X, Wang G, Shi R, Jiang K, Meng L, Ren H, Wu J, Hu Y. 2016. Enhanced tolerance and antitumor efficacy by docetaxel-loaded albumin nanoparticles. Drug Deliv. 23(8):2686–2696.
   PubMed Web of Science ®Google Scholar
• Tawfik SM, Azizov S, Elmasry MR, Sharipov M, Lee Y-I. 2020. Recent advances in nanomicelles delivery systems. Nanomaterials. 11(1):70.
   Web of Science ®Google Scholar
• Tian Y, Zhang H, Qin Y, Li D, Liu Y, Wang H, Gan L. 2018. Overcoming drug-resistant lung cancer by paclitaxel-loaded hyaluronic acid-coated liposomes targeted to mitochondria. Drug Dev Ind Pharm. 44(12):2071–2082.
   PubMed Web of Science ®Google Scholar
• Torres-Martinez Z, Delgado Y, Ferrer-Acosta Y, Suarez-Arroyo IJ, Joaquín-Ovalle FM, Delinois LJ, Griebenow K. 2021. Key genes and drug delivery systems to improve the efficiency of chemotherapy. Cancer Drug Resistance. 4:163.
   PubMedGoogle Scholar
• Tran TH, Ramasamy T, Choi JY, Nguyen HT, Pham TT, Jeong J-H, Ku SK, Choi H-G, Yong CS, Kim JO. 2015. Tumor-targeting, pH-sensitive nanoparticles for docetaxel delivery to drug-resistant cancer cells. Int J Nanomed. 10:5249–5262.
   PubMed Web of Science ®Google Scholar
• Varan G, Benito JM, Mellet CO, Bilensoy E. 2017. Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery. Beilstein J Nanotechnol. 8(1):1457–1468.
   PubMedGoogle Scholar
• Varshosaz J, Taymouri S, Hassanzadeh F, Haghjooy Javanmard S, Rostami M. 2015. Folated synperonic-cholesteryl hemisuccinate polymeric micelles for the targeted delivery of docetaxel in melanoma. Biomed Res Int. 2015:746093.
   PubMed Web of Science ®Google Scholar
• Vines JB, Yoon J-H, Ryu N-E, Lim D-J, Park H. 2019. Gold nanoparticles for photothermal cancer therapy. Front Chem. 7:167.
   PubMed Web of Science ®Google Scholar
• Vrignaud P, Semiond D, Benning V, Beys E, Bouchard H, Gupta S. 2014. Preclinical profile of cabazitaxel. Drug Des Devel Ther. 8:1851–1867.
   PubMed Web of Science ®Google Scholar
• Wan J, Qiao Y, Chen X, Wu J, Zhou L, Zhang J, Fang S, Wang H. 2018. Structure‐guided engineering of cytotoxic cabazitaxel for an adaptive nanoparticle formulation: enhancing the drug safety and therapeutic efficacy. Adv Funct Mater. 28(52):1804229.
   Web of Science ®Google Scholar
• Wang Q, Alshaker H, Böhler T, Srivats S, Chao Y, Cooper C, Pchejetski D. 2017. Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer. Sci Rep. 7(1):1–8.
   PubMed Web of Science ®Google Scholar
• Wang N, He T, Shen Y, Song L, Li L, Yang X, Li X, Pang M, Su W, Liu X, et al. 2016. Paclitaxel and tacrolimus coencapsulated polymeric micelles that enhance the therapeutic effect of drug-resistant ovarian cancer. ACS Appl Mater Interfaces. 8(7):4368–4377.
   PubMed Web of Science ®Google Scholar
• Wang Y-H, Li Y, Yang S-L, Yang L. 2005. Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J Chem Inf Model. 45(3):750–757.
   PubMed Web of Science ®Google Scholar
• Wang F, Porter M, Konstantopoulos A, Zhang P, Cui H. 2017. Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy. J Control Release. 267:100–118.
   PubMed Web of Science ®Google Scholar
• Wang S, Tan X, Li S, Zhou Y, Geng P, Hua A, Deng A, Yu Z. 2017. Indomethacin-based stimuli-responsive micelles combined with paclitaxel to overcome multidrug resistance. Oncotarget. 8(67):111281–111294.
   PubMedGoogle Scholar
• Wang G, Wang Z, Li C, Duan G, Wang K, Li Q, Tao T. 2018. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy. Biomed Pharmacother. 106:275–284.
   PubMed Web of Science ®Google Scholar
• Wang B, Yu X-C, Xu S-F, Xu M. 2015. Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma. J Nanobiotechnol. 13(1):1–11.
   PubMedGoogle Scholar
• Wang X, Zhang H, Chen X. 2019. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2(2):141–160.
   PubMedGoogle Scholar
• Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. 1971. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 93(9):2325–2327.
   PubMed Web of Science ®Google Scholar
• Wei X, Song M, Li W, Huang J, Yang G, Wang Y. 2021. Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance. Theranostics. 11(13):6334–6354.
   PubMed Web of Science ®Google Scholar
• Xie C, Zhang P, Zhang Z, Yang C, Zhang J, Wu W, Jiang X. 2015. Drug-loaded pseudo-block copolymer micelles with a multi-armed star polymer as the micellar exterior. Nanoscale. 7(29):12572–12580.
   PubMed Web of Science ®Google Scholar
• Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. 2020. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 25(9):2193.
   PubMed Web of Science ®Google Scholar
• Yin X, Luo L, Li W, Yang J, Zhu C, Jiang M, Qin B, Yuan X, Yin H, Lu Y, et al. 2019. A cabazitaxel liposome for increased solubility, enhanced antitumor effect and reduced systemic toxicity. Asian J Pharm Sci. 14(6):658–667.
   PubMed Web of Science ®Google Scholar
• Yu J, Hu F, Zhu Q, Li X, Ren H, Fan S, Qian B, Zhai B, Yang D. 2020. PD-L1 monoclonal antibody-decorated nanoliposomes loaded with Paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers. Nanoscale Res Lett. 15(1):1–13.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Cai T, Xia X, Zhang R, Chiba P, Cai Y. 2016. Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer. Drug Deliv. 23(9):3350–3357.
   PubMed Web of Science ®Google Scholar
• Zeng Y-Y, Zeng Y-J, Zhang N-N, Li C-X, Xie T, Zeng Z-W. 2019. The preparation, determination of a flexible complex liposome co-loaded with cabazitaxel and β-elemene, and animal pharmacodynamics on paclitaxel-resistant lung adenocarcinoma. Molecules. 24(9):1697.
   Web of Science ®Google Scholar
• Zhang L, Liu Z, Kong C, Liu C, Yang K, Chen H, Huang J, Qian F. 2018. Improving drug delivery of micellar paclitaxel against non‐small cell lung cancer by coloading itraconazole as a micelle stabilizer and a tumor vascular manipulator. Small. 14(51):1802112.
   Web of Science ®Google Scholar
• Zhang Z, Mei L, Feng S-S. 2012. Vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicine. Nanomedicine (Lond)). 7(11):1645–1647.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sriraman SK, Kenny HA, Luther E, Torchilin V, Lengyel E. 2016. Reversal of chemoresistance in ovarian cancer by co-delivery of a P-glycoprotein inhibitor and paclitaxel in a liposomal platform. Mol Cancer Ther. 15(10):2282–2293.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang L, Chan HF, Xie W, Chen S, He C, Wang Y, Chen M. 2017. Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells. Sci Rep. 7:46057.
   PubMed Web of Science ®Google Scholar
• Zhang C-G, Zhu W-J, Liu Y, Yuan Z-Q, Yang S-d, Chen W-L, Li J-Z, Zhou X-F, Liu C, Zhang X-N. 2016. Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy. Sci Rep. 6:23859.
   PubMed Web of Science ®Google Scholar
• Zhou S-F. 2008. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 38(7-8):802–832.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Liu S, Zhang Y, Yang X, Ma Y, Guan Z, Wu Y, Zhang L, Yang Z. 2017. Reductive nanocomplex encapsulation of cRGD-siRNA conjugates for enhanced targeting to cancer cells. Int J Nanomedicine. 12:7255–7272.
   PubMed Web of Science ®Google Scholar
• Zhu C-j, An C-g. 2017. Enhanced antitumor activity of cabazitaxel targeting CD44+ receptor in breast cancer cell line via surface functionalized lipid nanocarriers. Trop J Pharm Res. 16(6):1383–1390.
   Web of Science ®Google Scholar